Loading...
Loading...
VTVT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 22.0K |
| Gross Profit | -22.0K |
| Operating Expense | 7,427.0K |
| Operating I/L | -7,427.0K |
| Other Income/Expense | 1,653.0K |
| Interest Income | 100.0K |
| Pretax | -5,774.0K |
| Income Tax Expense | -1,275.0K |
| Net Income/Loss | -4,499.0K |
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of orally administered treatments for diabetes. The company's product pipeline includes TTP399, a liver-selective glucokinase activator for type 1 diabetes; HPP737, a non-CNS penetrant PDE4 inhibitor for inflammatory diseases and psoriasis; TTP273, a GLP-1 receptor agonist for cystic fibrosis related diabetes; HPP3033, an Nrf2 pathway activator for chronic diseases; azeliragon for inflammatory lung diseases and cancers; and HPP971 for renal diseases. Additionally, vTv Therapeutics Inc. has license and research agreements with various pharmaceutical partners, driving its revenue through product development and commercialization.
